Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Teva
Farmers Insurance
Dow
Colorcon
Mallinckrodt
Johnson and Johnson
McKinsey
Deloitte

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,809,394

« Back to Dashboard

Which drugs does patent 8,809,394 protect, and when does it expire?

Patent 8,809,394 protects LYSTEDA and is included in one NDA.

This patent has eight patent family members in two countries.
Summary for Patent: 8,809,394
Title:Tranexamic acid formulations
Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Inventor(s): Moore; Keith A. (Loveland, OH), Heasley; Ralph A. (Webster Grove, MO), Greiwe; Jeffrey S. (Ft. Thomas, KY), Facemire; John W. (Douglasville, GA), Modest; Jason D. (Minneapolis, MN)
Assignee: Ferring B.V. (Hoofddorp, NL)
Application Number:13/544,685
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 8,809,394

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ferring Pharms Inc LYSTEDA tranexamic acid TABLET;ORAL 022430-001 Nov 13, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,809,394

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,487,005 Tranexamic acid formulations ➤ Sign Up
8,957,113 Tranexamic acid formulations ➤ Sign Up
9,060,939 Tranexamic acid formulations ➤ Sign Up
7,947,739 Tranexamic acid formulations ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Healthtrust
Fish and Richardson
Baxter
Medtronic
Mallinckrodt
Cipla
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.